TNFRSF1B and ovarian carcinoma: Antibodies raised against the TNFα binding site of TNFR2 inhibited the proliferation of TNFR2+ Treg cells at low dosage and eliminated Tregs from ovarian cancer ascites and TNFR2+ OVCAR3 cells (15).